Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150


Detection of hypoxia with 18F-fluoromisonidazole (18F-FMISO) PET/CT in suspected or proven pancreatic cancer.

Segard T, Robins PD, Yusoff IF, Ee H, Morandeau L, Campbell EM, Francis RJ.

Clin Nucl Med. 2013 Jan;38(1):1-6. doi: 10.1097/RLU.0b013e3182708777.


Positron emission tomography/computed tomography imaging of residual skull base chordoma before radiotherapy using fluoromisonidazole and fluorodeoxyglucose: potential consequences for dose painting.

Mammar H, Kerrou K, Nataf V, Pontvert D, Clemenceau S, Lot G, George B, Polivka M, Mokhtari K, Ferrand R, Feuvret L, Habrand JL, Pouysségur J, Mazure N, Talbot JN.

Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):681-7. doi: 10.1016/j.ijrobp.2011.12.047.


Characterization of hypoxia in malignant pleural mesothelioma with FMISO PET-CT.

Francis RJ, Segard T, Morandeau L, Lee YC, Millward MJ, Segal A, Nowak AK.

Lung Cancer. 2015 Oct;90(1):55-60. doi: 10.1016/j.lungcan.2015.07.015.


Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.

Thureau S, Chaumet-Riffaud P, Modzelewski R, Fernandez P, Tessonnier L, Vervueren L, Cachin F, Berriolo-Riedinger A, Olivier P, Kolesnikov-Gauthier H, Blagosklonov O, Bridji B, Devillers A, Collombier L, Courbon F, Gremillet E, Houzard C, Caignon JM, Roux J, Aide N, Brenot-Rossi I, Doyeux K, Dubray B, Vera P.

J Nucl Med. 2013 Sep;54(9):1543-50. doi: 10.2967/jnumed.112.118083.


[(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression.

Rajendran JG, Wilson DC, Conrad EU, Peterson LM, Bruckner JD, Rasey JS, Chin LK, Hofstrand PD, Grierson JR, Eary JF, Krohn KA.

Eur J Nucl Med Mol Imaging. 2003 May;30(5):695-704.


Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-Fluoromisonidazole and 18F-FDG PET.

Cherk MH, Foo SS, Poon AM, Knight SR, Murone C, Papenfuss AT, Sachinidis JI, Saunder TH, O'Keefe GJ, Scott AM.

J Nucl Med. 2006 Dec;47(12):1921-6.


¹⁸F-HX4 hypoxia imaging with PET/CT in head and neck cancer: a comparison with ¹⁸F-FMISO.

Chen L, Zhang Z, Kolb HC, Walsh JC, Zhang J, Guan Y.

Nucl Med Commun. 2012 Oct;33(10):1096-102. doi: 10.1097/MNM.0b013e3283571016.


18F-fluoromisonidazole PET/CT: a potential tool for predicting primary endocrine therapy resistance in breast cancer.

Cheng J, Lei L, Xu J, Sun Y, Zhang Y, Wang X, Pan L, Shao Z, Zhang Y, Liu G.

J Nucl Med. 2013 Mar;54(3):333-40. doi: 10.2967/jnumed.112.111963.


Ex-vivo biodistribution and micro-PET/CT imaging of 18F-FDG, 18F-FLT, 18F-FMISO, and 18F-AlF-NOTA-PRGD2 in a prostate tumor-bearing nude mouse model.

Cheng Z, Wei R, Wu C, Qing H, Jiang X, Lu H, Chen S, Li X, Xu G, Ai H.

Nucl Med Commun. 2015 Sep;36(9):914-21. doi: 10.1097/MNM.0000000000000339.


Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies.

Cher LM, Murone C, Lawrentschuk N, Ramdave S, Papenfuss A, Hannah A, O'Keefe GJ, Sachinidis JI, Berlangieri SU, Fabinyi G, Scott AM.

J Nucl Med. 2006 Mar;47(3):410-8.


Correlation of (18)F-fluoromisonidazole PET findings with HIF-1α and p53 expressions in head and neck cancer: comparison with (18)F-FDG PET.

Norikane T, Yamamoto Y, Maeda Y, Kudomi N, Matsunaga T, Haba R, Iwasaki A, Hoshikawa H, Nishiyama Y.

Nucl Med Commun. 2014 Jan;35(1):30-5. doi: 10.1097/MNM.0000000000000010.


A prospective clinical trial of tumor hypoxia imaging with 18F-fluoromisonidazole positron emission tomography and computed tomography (F-MISO PET/CT) before and during radiation therapy.

Tachibana I, Nishimura Y, Shibata T, Kanamori S, Nakamatsu K, Koike R, Nishikawa T, Ishikawa K, Tamura M, Hosono M.

J Radiat Res. 2013 Nov 1;54(6):1078-84. doi: 10.1093/jrr/rrt033.


Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.

Santhosh S, Mittal BR, Bhasin D, Srinivasan R, Rana S, Das A, Nada R, Bhattacharya A, Gupta R, Kapoor R.

J Gastroenterol Hepatol. 2013 Feb;28(2):255-61. doi: 10.1111/jgh.12068.


[18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study.

Gagel B, Reinartz P, Demirel C, Kaiser HJ, Zimny M, Piroth M, Pinkawa M, Stanzel S, Asadpour B, Hamacher K, Coenen HH, Buell U, Eble MJ.

BMC Cancer. 2006 Mar 4;6:51.


Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study.

Lee NY, Mechalakos JG, Nehmeh S, Lin Z, Squire OD, Cai S, Chan K, Zanzonico PB, Greco C, Ling CC, Humm JL, Schöder H.

Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):2-13.


18F-fluoromisonidazole PET uptake is correlated with hypoxia-inducible factor-1α expression in oral squamous cell carcinoma.

Sato J, Kitagawa Y, Yamazaki Y, Hata H, Okamoto S, Shiga T, Shindoh M, Kuge Y, Tamaki N.

J Nucl Med. 2013 Jul;54(7):1060-5. doi: 10.2967/jnumed.112.114355.


Advantage of FMISO-PET over FDG-PET for predicting histological response to preoperative chemotherapy in patients with oral squamous cell carcinoma.

Sato J, Kitagawa Y, Yamazaki Y, Hata H, Asaka T, Miyakoshi M, Okamoto S, Shiga T, Shindoh M, Kuge Y, Tamaki N.

Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2031-41. doi: 10.1007/s00259-014-2810-y.


18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma.

Kikuchi M, Yamane T, Shinohara S, Fujiwara K, Hori SY, Tona Y, Yamazaki H, Naito Y, Senda M.

Ann Nucl Med. 2011 Nov;25(9):625-33. doi: 10.1007/s12149-011-0508-9.


(18)F-FDG-PET/CT findings in pancreatic metastasis.

Hu S, Zhang J, Zuo C, Cheng C, Liu Q, Sun G.

Radiol Med. 2015 Oct;120(10):887-98. doi: 10.1007/s11547-014-0473-1.

Items per page

Supplemental Content

Support Center